Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.
Restraints of the Global Urinary Tract Infection Treatment Market
Major factors hampering the growth of the urinary tract infection treatment market during the forecast period constitutes of low adoption of internet in some emerging economies.
Key features of the study:
Detailed Segmentation
Global Urinary Tract Infection Treatment Market, By Drug Type:
Global Urinary Tract Infection Treatment Market, By Disease Indication:
Global Urinary Tract Infection Treatment Market, By Distribution Channel:
Global Urinary Tract Infection Treatment Market, By Geography:
By Country:
By Country:
By Country:
By Country:
o Middle East:
By Country:
By Country/Region:
“*” marked represents similar segmentation in other categories in the respective section.
Restraints of the Global Urinary Tract Infection Treatment Market
Major factors hampering the growth of the urinary tract infection treatment market during the forecast period constitutes of low adoption of internet in some emerging economies.
Key features of the study:
- This report provides in-depth analysis of the global urinary tract infection treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global urinary tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global urinary tract infection treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Urinary Tract Infection Treatment Market, By Drug Type:
- Penicillin & Combinations
- Amoxicillin
- "Amoxicillin+ Clavulanate
- Potassium"
- Others
- Quinolones
- Ciprofloxacin
- Levofloxacin
- Nalidixic acid
- Norfloxacin
- Others
- Cephalosporin
- Ceftriaxone
- Cefuroxime
- Cefixime
- Cephalexin
- Aminoglycoside Antibiotics
- Amikacin
- Gentamicin
- "Sulphonamides (Sulfamethoxazole +
- Trimethoprim)"
- Azoles and Amphotericin B
- Tetracycline (Doxycycline)
- Nitrofurans (Nitrofurantoin)
- Other
Global Urinary Tract Infection Treatment Market, By Disease Indication:
- Complicated UTI
- Recurring Complicated UTI
- Uncomplicated UTI
- Neurogenic Bladder Infections
Global Urinary Tract Infection Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Urinary Tract Infection Treatment Market, By Geography:
- North America
By Country:
- U.S.
- Canada
- Europe
By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
o Middle East:
By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Cipla Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Johnson & Johnson
- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline
- Boehringer Ingelheim
- F. Hoffmann-La Roche Ltd.
- Iterum Therapeutics plc
- Novartis AG
- AstraZeneca Plc
- Allecra Therapeutics
- Shionogi Inc.
- Spero Therapeutics, Inc.
- Venatorx Pharmaceuticals.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Urinary Tract Infection Treatment Market, By Drug Type, 2019 - 2027 (US$ Mn)
5. Global Urinary Tract Infection Treatment Market, By Disease Indication, 2019 - 2027 (US$ Mn)
6. Global Urinary Tract Infection Treatment Market, By Distribution Channel, 2019 - 2027 (US$ Mn)
7. Global Urinary Tract Infection Treatment Market, By Regions, 2019 - 2027 (US$ Mn)
8. Competitive Landscape
9. Section
Companies Mentioned
A selection of companies mentioned in this report includes:
- Cipla Ltd.
- Johnson & Johnson
- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline
- Boehringer Ingelheim
- F. Hoffmann-La Roche Ltd.
- Iterum Therapeutics plc
- Novartis AG
- AstraZeneca Plc
- Allecra Therapeutics
- Shionogi Inc.
- Spero Therapeutics, Inc.
- Venatorx Pharmaceuticals.